SCHEMBL20366013

SCHEMBL20366013

NCC[C@H](NC=O)C(N)=O

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GABRR1 P24046 2/20 0.32
GSR P00390 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18105654 0.86 GSR (0.44) GSR
SCHEMBL13218612 0.86 GSR (0.44) GSR
SCHEMBL20340676 0.82
SCHEMBL7846388 0.81
SCHEMBL19955094 0.81 KMT2A (0.39)
SCHEMBL24158545 0.81 KMT2A (0.39)
SCHEMBL2923058 0.79 FOLH1 (0.44) GSR
SCHEMBL21202116 0.79 FOLH1 (0.44) GSR
SCHEMBL30088685 0.79 ADH1B (0.36)
SCHEMBL16572822 0.78 GABRR1 (0.33) GABRR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024059472-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2024-03-21 WO disclosed
WO-2018128826-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS CIDARA THERAPEUTICS, INC. (US) 2018-07-12 WO disclosed